This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula I:

$$A - D - B \qquad (I)$$

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

~~A is a substituted moiety of up to 40 carbon atoms of the formula: L-(M-L^1)$_q$, where L is a 5 or 6 membered cyclic structure bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and~~

~~B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6 member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,~~

~~wherein L^1 is substituted by at least one substituent selected from the group consisting of SO_2R_x, $C(O)R_x$ and $C(NR_y)R_z$,~~

~~R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,~~

~~R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~R_x is R_z or NR_aR_b where R_a and R_b are~~

~~a) independently hydrogen,~~

~~a carbon based moiety of up to 30 carbon atoms optionally containing~~

heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

$-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L^+ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

~~wherein Q is O , S , $N(R^7)$, $(CH_2)_m$, C(O) , CH(OH) , $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$ CHX^a , CX^a_2 , S $(CH_2)_m$ and $N(R^7)(CH_2)_m$, where m= 1-3, and X^a is halogen; and~~

~~Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of CN, CO_2R^7, $C(O)R^7$, $C(O)NR^7R^7$, NO_2, OR^7, SR^7 NR^7R^7, $NR^7C(O)OR^7$, $NR^7C(O)R^7$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of CN, CO_2R^7, COR^7, $C(O)NR^7R^7$, OR^7, SR^7, NO_2, NR^7R^7, $NR^7C(O)R^7$, and $NR^7C(O)OR^7$, with R^7 as defined above.~~

A is a substituted moiety of the formula:

$$\text{-L-M-L}^1\text{,}$$

wherein

L is phenyl, pyridinyl or pyrimidinyl,

L^1 is phenyl, pyridinyl or pyrimidinyl,

M is –O- or –S-,

wherein L^1 is substituted by -$C(O)NR_aR_b$ and

A is optionally additionally substituted with halogen, up to per-halo, and optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, CN, CO_2R^7, $C(O)R^7$, $C(O)NR^7R^7$, NO_2, OR^7, NR^7R^7, $NR^7C(O)OR^7$, $NR^7C(O)R^7$, C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkyl C_1-C_{10} alkoxy, and up to per-halosubstituted C_1-C_{10} alkoxy, and

wherein

-R_a and R_b are independently

a) hydrogen,

b) C_1 -C_{10} alkyl,

c) C_{3-10} cycloalkyl,

d) C_6 -C_{12} aryl,

e) C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S,

f) C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

g) C_7-C_{24} alkaryl,

h) substituted C_{1-10} alkyl,

i) substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O,

j) substituted C_{6-12} aryl,

k) substituted C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

l) substituted C_{7-24} alkaryl,

where R_a and R_b are a substituted group, they are substituted by

i) halogen up to per halo,

ii) hydroxy,

iii) C_{1-10} alkyl,

iv) C_{1-10} alkoxy,

v) up to per-halosubstituted C_1 -C_6 alkyl,

vi) C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

vii) C_{6-12} aryl,

viii) $-C(O)R_g$ where R_g is C_{1-10} alkyl;

or

-R_a and R_b combine together to form a 6 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 6 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O,

where the substituents are selected from the group consisting of

a) halogen up to per halo,

b) hydroxy,

c) C_{1-10} alkyl,

d) C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

f) C_{1-10} alkoxy,

g) C_6 -C_{12} aryl,

h) up to per-halosubstituted C_{1-6} alkyl,

i) up to per-halosubstituted C_6 -C_{12} aryl,

j) up to per halosubstituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

k) up to per-halosubstituted C_3-C_{12} hetaryl having 1-3 heteroatoms selected from N, S and O, and

l) -C(O)R_g , where R_g is C_{1-10} alkyl;

or

-one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L^1 to form a cyclic structure with at least 5 members,

wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of

a) halogen,

b) hydroxy,

c) C_1 -C_{10} alkyl,

d) C_3 -C_{12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

f) C_{1-10} alkoxy,

g) C_6 -C_{12} aryl,

h) up to per halo substituted C_{1-6} alkyl

i) up to per halo substituted C_6 -C_{12} aryl,

j) up to per halo substituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

k) up to per halo substituted C_3-C_{12} hetaryl having 1-3 heteroatoms selected from N, S and O, and

l) -C(O)R_g where R_g is C_{1-10} alkyl

or

- R_a and R_b are independently -OSi(R_f)$_3$ where R_f is

a) hydrogen,

b) C_{1-10} alkyl,

c) C_{1-10} alkoxy,

d) C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C_{6-12} aryl,

f) C_3-C_{12} hetaryl having 1-3 heteroatoms selected from O, S and N,

g) substituted C_{1-10} alkyl,

h) substituted C_1-C_{10} alkoxy,

i) substituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

j) substituted C_3-C_{12} hetaryl having 1-3 heteroatoms selected from O, S, and N, and

k) substituted phenyl,

where R_f is a substituted group it is substituted by halogen up to per halo, hydroxy, C_{1-10} alkyl, and up to per halo substituted C_{1-6} alkyl,

and

B is phenyl or pyridinyl;

and wherein B is optionally substituted with halogen, up to per-halo, and optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, CN, CO_2R^7, $C(O)R^7$, $C(O)NR^7R^7$, NO_2, OR^7, NR^7R^7, $NR^7C(O)OR^7$, $NR^7C(O)R^7$, C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkyl, C_1-C_{10} alkoxy, up to per-halosubstituted C_1-C_{10} alkoxy, phenyl and C_3-C_{12} heteroaryl having 1-3 heteroatoms selected from the group consisting of O, N and S,

wherein each R^7 is independently,

(a) hydrogen,

(b) C_1-C_{10} alkyl,

(c) up to per-halosubstituted C_1-C_{10} alkyl,

(d) C_1-C_{10} alkoxy,

(e) up to per-halosubstituted C_1-C_{10} alkoxy,

(f) phenyl, or

(g) up to per-halosubstituted phenyl.

2. Cancelled

3. (Currently Amended) A compound as in claim 1 wherein M is -O-~~one or more bridging groups selected from the group consisting of O, S, $N(R^7)$, $(CH_2)_m$, C(O), CH(OH), $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$, CHX^a, CX^a_2, S (CH_2) and $N(R^7)(CH_2)_m$, $(CH_2)_m$, where m=1-3, X^a is halogen~~

~~and where R^7 is as defined in claim 1~~.

4. (Original) A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

5. (Original) A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

6. (Currently Amended) A compound of claim 1 wherein B of Formula I is phenyl, and B is optionally substituted with 1-3 substituents which are independently -CN, $-NO_2$, halogen, C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkyl, C_1-C_{10} alkoxy, up to per-halosubstituted C_1-C_{10} alkoxy, $C(O)NR^7R^7$, phenoxy and $C(O)NR^7R^7$ substituted phenoxy

~~a substituted or unsubstituted six member aryl moiety or six member hetaryl moiety, said hetaryl moiety having 1 to 4 members selected from the group of hetaryl atoms consisting of nitrogen, oxygen and sulfur with the balance of the hetaryl moiety being carbon.~~

7. (Currently Amended) A compound of claim 1 wherein B of Formula I is phenyl, and B is optionally substituted with 1-3 substituents which are independently halogen, C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkyl or C_1-C_{10} alkoxy

~~an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in claim 1, a pyrimidinyl group substituted by a substituent selected from the group constituting of halogen and Wn, whereas W and n are as defined in Claim 1, or a substituted pyridyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in claim 1~~.

8. (Currently Amended) A compound of claim ~~6~~ 1 wherein B of Formula I is ~~a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyridyl group~~ phenyl, substituted 1 to 3 times by 1 or more substituents selected from the group consisting of ~~-CN,~~ halogen, C_1-C_6 ~~C_{10}~~ alkyl, C_1-C_6 ~~C_{10}~~ alkoxy, -OH, up to per halo substituted C_1-C_6 ~~C_{10}~~ alkyl, up to per halo substituted C_1-C_6 ~~C_{10}~~ alkoxy or phenyl substituted by halogen up to per halo.

9. (Currently Amended) A compound of claim 1, wherein L is phenyl, substituted with 1-3 substituents which are, independently, -CN, -C_1-C_{10} alkyl, up to per-halosubstituted -C_1-C_{10} alkyl, -NO_2, -C_1-C_{10} alkoxy, or halogen

~~, the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are selected from the group consisting of halogen and Wn wherein W and n are as defined in claim 1.~~

10. (Currently Amended) A compound of claim 8, wherein L is phenyl, substituted with 1-3 substituents which are, independently, -CN, -C_1-C_{10} alkyl, up to per-halosubstituted -C_1-C_{10} alkyl, -NO_2, -C_1-C_{10} alkoxy, or halogen

~~, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.~~

11. (Currently Amended) A compound of claim 1, wherein ~~said substituted cyclic moiety~~ L^1 is phenyl or pyridinyl, optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, -CN, CO_2R^7, $C(O)R^7$, $C(O)NR^7R^7$, NO_2, OR^7, NR^7R^7, $NR^7C(O)OR^7$, $NR^7C(O)R^7$, C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkyl C_1-C_{10} alkoxy and up to per-halosubstituted C_1-C_{10} alkoxy and halogen

~~comprises a 5 to 6 membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur~~.

12. (Currently Amended) A compound of claim 1, wherein ~~said substituted cyclic moiety~~ L^1 is pyridinyl ~~phenyl, pyridinyl or pyrimidinyl~~.

13. (Currently Amended) A compound of claim 6 ~~3~~, wherein ~~said substituted cyclic moiety~~ L^1 is pyridinyl ~~phenyl, pyridinyl or pyrimidinyl~~ .

14. (Currently Amended) A compound of claim 7 ~~6~~, wherein ~~said~~

~~substituted cyclic moiety~~ L^1 is pyridinyl ~~phenyl, pyridinyl or pyrimidinyl~~.

15. (Currently Amended) A compound of claim 8, wherein ~~said substituted cyclic moiety~~ L^1 is pyridinyl ~~phenyl, pyridinyl or pyrimidinyl~~ .

16. (Currently Amended) A compound of claim 9, wherein ~~said substituted cyclic moiety~~ L^1 is pyridinyl ~~phenyl, pyridinyl or pyrimidinyl~~ .

17. (Currently Amended) A compound of claim 10, wherein ~~said substituted cyclic moiety~~ L^1 is pyridinyl ~~phenyl, pyridinyl or pyrimidinyl~~ .

18. (Currently Amended) A compound of claim 14, wherein M is –O- ~~one or more bridging groups selected from the group consisting of O, S, N(R^7), $(CH_2)_m$, C(O), CH(OH), $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$, CHX^a, CX^a_2, S $(CH_2)_m$ and N(R^7)$(CH_2)_m$, where m= 1-3, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.~~

19. (Currently Amended) A compound of claim 15, wherein M is –O- ~~one or more bridging groups selected from the group consisting of O, S, N(R^7), $(CH_2)_m$, C(O), CH(OH), $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$, CHX^a, CX^a_2, S $(CH_2)_m$ and N(R^7)$(CH_2)_m$, where m= 1-3, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.~~

20. (Currently Amended) A compound of claim 16, wherein M is –O- ~~one or more bridging groups selected from the group consisting of O, S, N(R^7), $(CH_2)_m$, C(O), CH(OH), $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$, CHX^a, CX^a_2, S $(CH_2)_m$ and N(R^7)$(CH_2)_m$, where m= 1-3, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.~~

21. (Currently Amended) A compound of claim 17, wherein M is –O- ~~one or more bridging groups selected from the group consisting of O, S, N(R^7), $(CH_2)_m$, C(O), CH(OH), $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$, CHX^a, CX^a_2, S $(CH_2)_m$ and N(R^7)$(CH_2)_m$, where m= 1-3, X^a is halogen and R^7 is~~

~~hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.~~

22. (Original) A compound of claim 1 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.

23. (Currently Amended) A compound of claim 12 ~~13~~ wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.

24. (Original) A compound of claim 18 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.

25. (Original) A compound of claim 19 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.

26. (Original) A compound of claim 20 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.

27. (Original) A compound of claim 21 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.

28. (Currently Amended) A compound of claim 1 wherein L^1 is substituted by ~~-C(O)R$_x$~~ -C(O)NR_aR_b and -R_a and R_b are independently

m) hydrogen,

n) C_1 -C_{10} alkyl,

o) phenyl,

p) pyridinyl,

q) C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

r) substituted C_{1-10} alkyl,

s) substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O,

t) substituted phenyl,

u) substituted pyridinyl,

where R_a and R_b are a substituted group, they are substituted by

i) halogen up to per halo,

ii) hydroxy,

iii) C_{1-10} alkyl,

iv) C_{1-10} alkoxy,

v) up to per-halosubstituted C_1 -C_6 alkyl, and

vi) C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

vii) C_{6-12} aryl, or

viii) $-C(O)R_g$ where R_g is C_{1-10} alkyl.

29. (Currently Amended) A compound of claim 12 wherein L^1 is substituted by $-C(O)NR_aR_b$ and $-R_a$ and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy ~~1 wherein L^+ is not phenyl and is substituted by $-SO_2R_*$~~ .

30. (Currently Amended) A compound of claim 13 wherein L^1 is substituted by $-C(O)NR_aR_b$ and $-R_a$ and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy ~~1 wherein L^+ is substituted only by $-C(O)R_*$~~ .

31. (Currently Amended) A compound of claim 14 wherein L^1 is substituted by $-C(O)NR_aR_b$ and $-R_a$ and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy (Currently Amended) A compound of claim 1 wherein L^1 is substituted only by $-SO_2R_*$ NR_aR_b.

32. (Currently Amended) A compound of claim 15 wherein L^1 is substituted by $-C(O)NR_aR_b$ and $-R_a$ and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy (Original) A compound of claim 1 wherein L^1 is substituted

by -C(O)R_x or -SO_2R_x, wherein R_x is NR_aR_b.

33. (Currently Amended) A compound of claim 16 wherein L^1 is substituted by -C(O)NR_aR_b and -R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy (Currently Amended) A compound of claim 13 wherein L^1 is substituted by -C(O)R_x or -SO_2R_x, wherein R_x is NR_aR_b, and R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy

~~a) independently hydrogen,~~

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

~~$OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

34. (Currently Amended) A compound of claim 17 wherein L^1 is substituted by -C(O)NR_aR_b and -R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy (Currently Amended) A compound of claim 14 ~~18~~ wherein L^1

is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy

~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

35. (Currently Amended) A compound of claim 18 wherein L^1 is substituted by $-C(O)NR_aR_b$ and $-R_a$ and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy (Currently Amended) A compound of claim 15 ~~19~~ wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy

~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

36. (Currently Amended) A compound of claim 19 wherein L^1 is substituted by $-C(O)NR_aR_b$ and $-R_a$ and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy (Currently Amended) A compound of claim 16 ~~20~~ wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy

~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

37. (Currently Amended) A compound of claim 21 wherein L^1 is substituted by $-C(O)NR_aR_b$ and $-R_a$ and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy (Currently Amended) A compound of claim 17 ~~21~~ wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy

~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing~~

~~heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

38. (Currently Amended) A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

~~A is a substituted moiety of up to 40 carbon atoms of the formula: L-$(M-L^+)_q$;~~ ~~where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D, L^+ comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^+ contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and~~

~~B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,~~

~~wherein L^+ is substituted by at least one substituent selected from the group consisting of $-SO_2R_x$; $-C(O)R_x$ and $-C(NR_y)R_z$, R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,~~

~~R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~R_x is R_z or NR_aR_b where R_a and R_b are~~

~~a) independently hydrogen,~~

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain~~

heteroatoms selected from N, S and O and are optionally substituted by halogen, or

—OSi(R_f)$_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R_a or R_b is C(O), a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per halo, and Wn, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-, $-N(R^7)$-, $-(CH_2)_m$-, -C(O)-, -CH(OH)-, $-(CH_2)_mO$-, $-(CH_2)_mS$-, $-(CH_2)_mN(R^7)$-, $-O(CH_2)_m$-, $-CHX^a$-, $-CX^a_2$-, $-S(CH_2)_m$- and $-N(R^7)(CH_2)_m$-

~~, where m= 1-3, and X^a is halogen;~~

~~Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of CN, CO_2R^7, $C(O)R^7$, $C(O)NR^7R^7$, NO_2, OR^7, SR^7 NR^7R^7, $NR^7C(O)OR^7$, $NR^7C(O)R^7$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents are selected from the group consisting of CN, CO_2R^7, COR^7, $C(O)NR^7R^7$, OR^7, SR^7, NO_2, NR^7R^7, $NR^7C(O)R^7$, and $NR^7C(O)OR^7$, with R^7 as defined above; and~~

~~wherein M is one or more bridging groups selected from the group consisting of O, S, $N(R^7)$, $(CH_2)_m$, C(O), CH(OH), $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$ CHX^a, CX^a_2, $S(CH_2)_m$ and $N(R^7)(CH_2)_m$, where m= 1-3, X^a is halogen~~

A is a substituted moiety of the formula:

$$\text{-L-M-L}^1,$$

wherein

L is phenyl or pyridinyl

L^1 is phenyl or pyridinyl and

M is -O- or -S-

wherein

L^1 is substituted by $-C(O)NR_aR_b$ and

A is optionally additionally substituted with halogen, up to per-halo, and optionally substituted with 1-3 substituents independently selected from the group consisting of

methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl,

up to per-halosubstituted methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl,

OR^7, where R^7 is hydrogen; methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl,

NR^7R^7 , where each R^7 is independently hydrogen, , ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl,

NO_2, and –CN;

wherein

-R_a and R_b are independently

v) hydrogen,

w) C_1 -C_{10} alkyl,

x) C_{3-10} cycloalkyl,

y) C_6 -C_{12} aryl,

z) C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S,

aa) C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

bb) C_7-C_{24} alkaryl,

cc) substituted C_{1-10} alkyl,

dd) substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O,

ee) substituted C_{6-12} aryl,

ff) substituted C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

gg) substituted C_{7-24} alkaryl,

where R_a and R_b are a substituted group, they are substituted by

i) halogen up to per halo,

ii) hydroxy,

iii) C_{1-10} alkyl,

iv) C_{1-10} alkoxy,

v) up to per-halosubstituted C_1 -C_6 alkyl,

vi) C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

vii) C_{6-12} aryl,

viii) $-C(O)R_g$ where R_g is C_{1-10} alkyl;

or

-R_a and R_b combine together to form a 6 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 6 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O,

where the substituents are selected from the group consisting of

a) halogen up to per halo,

b) hydroxy,

c) C_{1-10} alkyl,

d) C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

f) C_{1-10} alkoxy,

g) C_6 -C_{12} aryl,

h) up to per-halosubstituted C_{1-6} alkyl,

i) up to per-halosubstituted C_6 -C_{12} aryl,

j) up to per halosubstituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

k) up to per-halosubstituted C_3-C_{12} hetaryl having 1-3 heteroatoms selected from N, S and O, and

l) -C(O)R_g , where R_g is C_{1-10} alkyl;

or

-one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L^1 to form a cyclic structure with at least 5 members,

wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of

a) halogen,

b) hydroxy,

c) C_1 -C_{10} alkyl,

d) C_3 -C_{12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

f) C_{1-10} alkoxy,

g) C_6 -C_{12} aryl,

h) up to per halo substituted C_{1-6} alkyl

i) up to per halo substituted C_6 -C_{12} aryl,

j) up to per halo substituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

k) up to per halo substituted C_3-C_{12} hetaryl having 1-3 heteroatoms selected from N, S and O, and

l) $-C(O)R_g$ where R_g is C_{1-10} alkyl

or

- R_a and R_b are independently $-OSi(R_f)_3$ where R_f is

a) hydrogen,

b) C_{1-10} alkyl,

c) C_{1-10} alkoxy,

d) C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C_{6-12} aryl,

f) C_3-C_{12} hetaryl having 1-3 heteroatoms selected from O, S and N,

g) substituted C_{1-10} alkyl,

h) substituted C_1-C_{10} alkoxy,

i) substituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,

j) substituted C_3-C_{12} hetaryl having 1-3 heteroatoms selected from O, S, and N, and

k) substituted phenyl,

where R_f is a substituted group it is substituted by halogen up to per halo, hydroxy, C_{1-10} alkyl, and up to per halo substituted C_{1-6} alkyl,

and

B is selected from the group consisting of phenyl and pyridinyl and wherein B is optionally substituted with halogen, up to pre-halo, and optionally substituted with 1-3 substituents independently selected from the group consisting of methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl, up to per-halosubstituted methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl, OR^7, where R^7 is hydrogen; methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl, up to per-halosubstituted alkoxy of the formula OR^7, where R^7 is methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl, NR^7R^7, where each R^7 is independently hydrogen, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl, NO_2 and –CN.

39. (Currently Amended) A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

~~A is a substituted moiety of up to 40 carbon atoms of the formula: L-(M-L^+)$_q$;~~

~~where L is a substituted or unsubstituted phenyl or pyperitoneal moiety bound directly to D, L^+ comprises a substituted phenyl, peritoneal or pyrimidinyl moiety, M is a bridging group having at least one atom, q is an integer of from 1-3; and~~

~~B is a substituted or unsubstituted phenyl or pyridine group bound directly to D,~~

~~wherein L^+ is substituted by at least one substituent selected from the group consisting of $-SO_2R_x$, $-C(O)R_x$ and $-C(NR_y)R_z$;~~

~~R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and ;~~

~~R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~R_x is R_z or NR_aR_b where R_a and R_b are~~

~~a) independently hydrogen,~~

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

~~$-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and~~

optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R_a or R_b is C(O), a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per halo, and Wn, where n is 0-3;

wherein each W is independently selected from the group consisting of CN, CO_2R^7, $C(O)NR^7R^7$, $C(O)R^7$, NO_2, OR^7, SR^7, NR^7R^7, $NR^7C(O)OR^7$, $NR^7C(O)R^7$, Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of CN, CO_2R^7, $C(O)R^7$, $C(O)NR^7R^7$, OR^7, SR^7, NR^7R^7, NO_2, $NR^7C(O)R^7$, $NR^7C(O)OR^7$ and halogen up to per halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is O, S, $N(R^7)$, $(CH_2)_m$, C(O), CH(OH), $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$, CHX^a, CX^a_2, $S(CH_2)_m$ and $N(R^7)(CH_2)_m$, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally

~~substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$ $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of –CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, and $-NR^7C(O)OR^7$; and~~

~~wherein M is one or more bridging groups selected from the group consisting of –O–, –S–, $-N(R^7)-$, $-(CH_2)_m-$, $-C(O)-$, $-CH(OH)-$, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ $-CHX^a-$, $-CX^a_2-$, $-S-(CH_2)_m-$ and $-N(R^7)(CH_2)_m-$, where m= 1-3, X^a is halogen.~~

A is a substituted moiety of the formula:

$$-L-M-L^1,$$

wherein

L is phenyl

L^1 is pyridinyl and

M is -O- ,

wherein

L^1 is substituted by $-C(O)NR_aR_b$ and

A is optionally additionally substituted with halogen, up to per-halo, and optionally substituted with 1-3 substituents independently selected from the group consisting of methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl, up to per-halosubstituted methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl, OR^7, NR^7R^7, NO_2, and –CN;

each R^7 is independently hydrogen, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl,

$-R_a$ and R_b are independently

a) hydrogen,

b) C_1 -C_{10} alkyl,

c) C_{1-10} alkyl substituted by

i) halogen up to per halo,

ii) methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl,

iii) up to per-halosubstituted methyl or ethyl,

vi) pyridinyl and

vii) phenyl

and

B is phenyl,

wherein B is optionally substituted with halogen, up to pre-halo, and optionally substituted with 1-3 substituents independently selected from the group consisting of methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl, up to per-halosubstituted methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl, OR^7, where R^7 is hydrogen; methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl, and up to per-halosubstituted alkoxy of the formula OR^7, where R^7 is methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl or tert-butyl,

wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

40. (Original) A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

41. (Original) A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

42. (Original) A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

43. (Original) A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

44. (Currently Amended) A compound as in claim 38 wherein substituents for B and L and additional substituents for L^1, are selected from the group consisting of methyl, methoxy, halogen, t-butyl and trifluoromethyl.

~~C_1-C_{10} alkyl up to per halo substituted C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.~~

45. (Currently Amended) A compound as in claim 39 wherein substituents for B and L and additional substituents for L^1, are selected from the group consisting of methyl, methoxy, halogen, t-butyl and trifluoromethyl.

~~C_1-C_{10} alkyl up to per halo substituted C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.~~

46. (Currently Amended) A compound of claim 38 wherein L^1 is pyridyl and R_a and R_b are independently hydrogen, methyl, ethyl or propyl ~~substituted by $C(O)R_x$ or SO_2R_x.~~

47. (Currently Amended) A compound of claim 39 wherein R_a and R_b are independently hydrogen, methyl, ethyl or propyl ~~L^1 substituted by $C(O)R_x$ or SO_2R_x.~~

48. (Currently Amended) A compound of claim 46 wherein L^1 is substituted by $C(O)HCH_3$ ~~substituted by $C(O)R_x$ R_x is NR_aR_b and R_a and R_b are independently R_z.~~

49. (Currently Amended) A compound of claim 47 wherein L^1 is substituted by $C(O)HCH_3$ ~~substituted by $C(O)R_x$ R_x is NR_aR_b and R_a and R_b are independently R_z.~~

50. (Currently Amended) A ~~compound of claim 1 which is~~ a pharmaceutically acceptable salt of a compound of formula I of claim 1 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

~~selected from the group consisting of~~

~~a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and~~

~~b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.~~

51. cancelled

52. cancelled

53. (Currently Amended) A ~~compound of claim 38 which is a~~ pharmaceutically acceptable salt of a compound of ~~formula I~~ claim 38 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

~~selected from the group consisting of~~

~~a) basic salts of organic acids and inorganic acids selected from the group~~

~~consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and~~

~~b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.~~

54. (Currently Amended) A ~~compound of claim 39 which is a~~ pharmaceutically acceptable salt of a compound of ~~formula I of~~ claim 39 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

~~selected from the group consisting of~~

~~a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and~~

~~b) acid salts of organic and inorganic bases containing cations selected~~

~~from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.~~

55. (Currently Amended) A pharmaceutical composition for the treatment of a cancerous cell growth mediated by raf kinase comprising a compound of claim 1 ~~or a pharmaceutically acceptable salt of a compound of formula I,~~ and a physiologically acceptable carrier.

56. Cancelled

57. Cancelled

58. (Currently Amended) A pharmaceutical composition for the treatment of a cancerous cell growth mediated by raf kinase comprising a compound of claim 38 and a physiologically acceptable carrier ~~of claim 55 wherein the compound of formula I is that defined in claim 38~~.

59. (Currently Amended) A pharmaceutical composition for the treatment of a cancerous cell growth mediated by raf kinase comprising a compound of claim 39 and a physiologically acceptable carrier ~~of claim 55 wherein the compound of formula I is that defined in claim 39~~.

60. (Currently Amended) A pharmaceutical composition as in claim 55 wherein the compound of claim 1 is a pharmaceutically acceptable salt of a compound of formula I therein ~~A compound selected from the group consisting of~~

~~3-tert butyl phenyl ureas of Table 1 above;~~

~~5-tert butyl-2-methoxyphenyl ureas of Table 2 above;~~

~~5-(trifluoromethyl)-2-phenyl ureas of Table 3 above;~~

~~3-(trifluoromethyl)-4-chlorophenyl ureas of Table 4 above;~~

~~3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;~~

~~5-(trifluoromethyl)-4-chloro-2-methoxyphenyl ureas of Table 6 above; and~~

~~ureas 101-103 in Table 7 above.~~

61. (Currently Amended) A pharmaceutical composition as in claim 58 wherein the compound of claim 38 is a pharmaceutically acceptable salt of a compound of formula I therein ~~A compound selected from the group consisting of~~

~~the 3-tert butyl phenyl ureas:~~

~~*N*-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl urea and~~

~~*N*-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl urea;~~

~~the 5-*tert*-butyl-2-methoxyphenyl ureas:~~

~~*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,~~

~~*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,~~

~~*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and~~

~~*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;~~

~~the 2-methoxy-5-trifluoromethyl)phenyl ureas:~~

~~*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,~~

~~*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,~~

~~*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,~~

~~*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,~~

~~*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,~~

~~N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and~~

~~*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;~~

~~the 4-chloro-3-(trifluoromethyl)phenyl ureas:~~

~~*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl)~~

~~urea,~~

~~*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,~~

~~*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and~~

~~*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.~~

~~the 4-romo-3-(trifluoromethyl)phenyl ureas:~~

~~*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,~~

~~*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,~~

~~*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,~~

~~*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and~~

~~*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and~~

~~the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:~~

~~*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,~~

~~*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,~~

~~*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and~~

~~*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea~~.

62. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering an effective amount of a compound of Formula I of claim 1.

63. cancelled

64. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering an effective amount of a compound of Formula I of claim 38.

65. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering an effective amount of a compound of Formula I of claim 39.

66. Cancelled

67. Cancelled

68. (NEW) A compound as in claim 1 wherein B, L and L^1 follow one of the following of combinations:

B= phenyl, L=phenyl and L^1 is phenyl,
B= phenyl, L=pyridinyl and L^1 is phenyl,
B=pyridinyl, L= phenyl and L^1 is phenyl, or
B= phenyl, L=phenyl and L^1 is pyridinyl.

69. (NEW) A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of claim 68 and a physiologically acceptable carrier.

70. (NEW) A pharmaceutical composition for the treatment of a cancerous cell growth which comprises a pharmaceutically acceptable salt of claim 68, wherein said salt is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, acetic acid, trifluoroacetic acid, sulfonic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.